Safe dosage range and dosage recommendations of eflornithine (IWILFIN) tablets

Eflornithine (IWILFIN) is a new type of oral antimetabolite drug mainly used to treat specific types of solid tumors and some hematological malignancies. Its mechanism of action is to inhibit tumor cell proliferation by inhibiting nucleotide synthesis in cancer cells and blocking DNA replication. As an oral tablet, correct dosage control and administration are crucial to ensure efficacy and reduce adverse reactions.

The dosage of eflornithine (IWILFIN) tablets can be individually adjusted according to the patient's body surface area (BSA) to ensure efficacy while reducing the risk of adverse reactions. The specific recommended dosage is as follows:

Body surface area>1.5 m²: The recommended dose is 768 mg (4 tablets), taken orally twice daily.

Body surface area 0.75–1.5 m²: The recommended dose is 576 mg (3 tablets), taken orally twice daily.

Body surface area 0.5–＜0.75 m²: The recommended dose is 384 mg (2 tablets), taken orally twice daily.

Body surface area 0.25–＜0.5 m²: The recommended dose is 192 mg (1 tablet), taken orally twice daily. In terms of taking recommendations, eflornithine tablets should be taken orally regularly under the guidance of a doctor. It is generally recommended to take the medicine at a fixed time every day. You can choose to take it before or after meals according to the drug instructions, but it must be consistent to ensure stable blood concentration. If mild gastrointestinal discomfort occurs, it can be taken with a small amount of food, but high-fat, greasy or irritating foods should be avoided. At the same time, attention should be paid to swallowing the medicine completely and not to break it into pieces or chew it randomly to avoid affecting absorption.

During the treatment process, patients need to regularly monitor blood routine, liver and kidney function and related biochemical indicators in order to detect and deal with adverse reactions in a timely manner. If there is an obvious drop in blood cells or abnormal liver function, the drug should be temporarily discontinued or the dosage should be adjusted, and intervention measures should be taken under the guidance of a doctor. Generally speaking, when eflornithine tablets are used within a safe dosage range, combined with regular medication and monitoring and management, better efficacy can be achieved while minimizing risks.

Reference link:https://www.drugs.com